PMID- 38189411
OWN - NLM
STAT- Publisher
LR  - 20240108
IS  - 2737-5935 (Electronic)
IS  - 0037-5675 (Linking)
DP  - 2024 Jan 8
TI  - Safety and efficacy of dupilumab in adult atopic dermatitis in Singapore.
LID - 10.4103/singaporemedj.SMJ-2023-031 [doi]
AB  - INTRODUCTION: Dupilumab, a biologic approved for treatment of moderate-to-severe 
      atopic dermatitis (AD), has been reported to be largely effective with minimal 
      adverse effects. However, being a targeted therapy, its effectiveness and side 
      effects are expected to be varied in a heterogeneous ethnic population. 
      Currently, the majority of studies on dupilumab are based on Western populations. 
      METHODS: A retrospective cohort of 51 patients with moderate-to-severe AD treated 
      with dupilumab at a tertiary skin institute from January 2018 to February 2020 
      was included. Outcome measures such as Scoring Atopic Dermatitis (SCORAD), Eczema 
      Area and Severity Index (EASI) and Dermatology Quality of Life Index (DLQI) were 
      analysed at baseline and after 16 weeks of treatment. Laboratory tests at the 
      respective time points were also measured. RESULTS: Patients treated with 
      dupilumab showed consistent reduction in body surface area (BSA) involved, 
      SCORAD, EASI and DLQI scores. Concurrently, serum immunoglobulin E (IgE) and 
      absolute eosinophil count showed a downward trend at 4 months of treatment. There 
      was a transient increase in mean serum IgE at 1 month of dupilumab treatment. 
      Also, 42.0% and 35.3% of patients developed eye symptoms, and head and neck 
      dermatitis, respectively, but there were no major adverse events reported. 
      Childhood-onset AD was more likely to have improved BSA scores compared to 
      adult-onset AD. CONCLUSIONS: Our study confirms the efficacy of dupilumab with 
      real-world data in an adult Asian population. Higher proportions of eye symptoms, 
      and head and neck dermatitis were observed in our cohort compared to other Asian 
      clinical cohort studies. Further studies are needed to evaluate these 
      differences.
CI  - Copyright (c) 2024 Copyright: (c) 2024 Singapore Medical Journal.
FAU - Yew, Yik Weng
AU  - Yew YW
AD  - Research Division, National Skin Centre, Singapore.
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
FAU - Zhao, Xiahong
AU  - Zhao X
AD  - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
FAU - Yong, Adeline Mei Yan
AU  - Yong AMY
AD  - Division of Dermatology, University Medicine Cluster, National University Health 
      System, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20240108
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
SB  - IM
EDAT- 2024/01/08 12:43
MHDA- 2024/01/08 12:43
CRDT- 2024/01/08 09:47
PHST- 2023/02/20 00:00 [received]
PHST- 2023/03/29 00:00 [accepted]
PHST- 2024/01/08 12:43 [medline]
PHST- 2024/01/08 12:43 [pubmed]
PHST- 2024/01/08 09:47 [entrez]
AID - 00077293-990000000-00077 [pii]
AID - 10.4103/singaporemedj.SMJ-2023-031 [doi]
PST - aheadofprint
SO  - Singapore Med J. 2024 Jan 8. doi: 10.4103/singaporemedj.SMJ-2023-031.